异基因造血干细胞移植后免疫性血细胞减少:挑战、对策与未来方向
异基因造血干细胞移植后免疫介导的血细胞减少罕见,病理生理不明,可能源于免疫失调。诊断困难,需与多种重叠并发症鉴别。治疗需多学科协作,从观察至靶向治疗,强烈免疫抑制增加感染和复发风险,当前治疗基于非移植患者经验。
要点
- 异基因HSCT后免疫性血细胞减少罕见,病理生理不明,可能源于免疫失调。
- 回顾性研究识别的危险因素需谨慎解读,不能推广至异质性患者群体。
- 治疗需多学科协作,强烈免疫抑制增加感染和复发风险。
核心结论
- 异基因造血干细胞移植后免疫介导的血细胞减少罕见,病理生理不明,诊断困难,治疗需多学科协作,当前治疗基于非移植患者经验。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 免疫介导的贫血、血小板减少和中性粒细胞减少可单独或联合发生,病理生理不明,可能源于免疫失调。
- 回顾性研究已识别该并发症的危险因素,但需谨慎解读,不应推广至异质性患者群体。
- 临床病程高度可变,治疗从观察至对症措施和定向治疗。
- 强烈免疫抑制与感染和复发风险增加相关。
- 浆细胞定向治疗、免疫调节和受体刺激剂可用于治疗免疫介导的血细胞减少。
临床怎么用
- 诊断需提高对该并发症的认识,并与多种其他可能重叠的并发症鉴别。
- 治疗需多学科协作,范围从观察至对症措施和定向治疗。
- 当前治疗基于非移植患者的方法,浆细胞定向治疗、免疫调节和受体刺激剂可用。
局限性
- 危险因素来自回顾性研究,需谨慎解读,不应推广至异质性患者群体。
- 当前治疗基于非移植患者经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-mediated cytopenia after allogeneic haematopoietic stem-cell transplantation is rare. The pathophysiology of immune-mediated anaemia, thrombocytopenia, and neutropenia, which occur alone or in combination with other cytopenias, is unclear and most probably a consequence of immune dysregulation. Risk factors for this complication have been identified in retrospective studies but these should be interpreted with caution and should not be generalised to this heterogeneous patient population. Diagnosis is challenging, requires awareness of such complications, and has to be differentiated from a multitude of other, and sometimes overlapping, possible complications. The clinical course of immune-mediated cytopenia is highly variable. Treatment requires an interdisciplinary approach and ranges from observation to symptomatic measures and directed therapies. Intensive immunosuppression is associated with an increased risk of infections and relapse, and current treatments are based on approaches in patients who have not undergone transplantation. Plasma cell-directed therapies, immunomodulation, and receptor-stimulating agents can be used to treat immune-mediated cytopenia.
引用
- Baur K, Buser AS, Infanti L, et al. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol. 2021. PMID: 33636143. doi:10.1016/S2352-3026(20)30404-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。